📰 Solid Tumors News
Page 45 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
May 27, 2022
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
May 27, 2022
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 - read this article along with other careers information, tips and advice on BioSpace
May 27, 2022
Doctors with Cancer Treatment Centers of America, part of City of Hope, will also share innovative research City of Hope, one of the largest cancer re
May 26, 2022
- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) -- Responses occurred across subgroups, with greater response
May 26, 2022
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of...
May 26, 2022
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of...
May 24, 2022
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer - NCT05081492
May 23, 2022
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer - read this article along with other careers information, tips and advice on BioSpace
May 23, 2022
- Data Accepted for Presentation at ESMO World Congress on Gastrointestinal Cancer - Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical
May 20, 2022
Fred Hutch scientists have identified a subset of immune-calming T cells that show up in great numbers in head and neck cancers, but not in similar tissues inflamed by gum diseases. This odd group of T cells have somehow been tricked into protecting these solid tumors from immune assault, but now might be precisely targeted by drugs to lift that protective shield.